Search Clinical Trials
| Sponsor Condition of Interest |
|---|
|
A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement
Elevar Therapeutics
FGFR2 Gene Fusion/Rearrangement
Other Solid Tumors, Adult
The goal of this clinical trial is to evaluate if lirafugratinib is efficacious and safe
to treat adult patients with previously treated, unresectable, locally advanced or
metastatic solid tumors (excluding cholangiocarcinoma) harboring FGFR2 fusion or
rearrangement.
Participants will:
- Take1 expand
The goal of this clinical trial is to evaluate if lirafugratinib is efficacious and safe to treat adult patients with previously treated, unresectable, locally advanced or metastatic solid tumors (excluding cholangiocarcinoma) harboring FGFR2 fusion or rearrangement. Participants will: - Take lirafugratinib regularly as instructed by their study doctor. - Visit the clinic as instructed for checkups and tests. - Keep a diary recording each time a dose of lirafugratinib is taken. Type: Interventional Start Date: Jun 2026 |
|
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123)1
Novartis Pharmaceuticals
Progressive Metastatic Castrate Resistant Prostate Cancer
This is a two-part, Phase I/II, open-label, global, multicenter study assessing the
safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462
(luxdegalutamide) versus standard of care in participants with progressive metastatic
castrate resistant prostate cancer (mCRPC). expand
This is a two-part, Phase I/II, open-label, global, multicenter study assessing the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) versus standard of care in participants with progressive metastatic castrate resistant prostate cancer (mCRPC). Type: Interventional Start Date: Oct 2025 |
|
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patie1
Novartis Pharmaceuticals
Metastatic Hormone-sensitive Prostate Cancer
This Phase II study aims to evaluate efficacy and safety of the combination of JSB462
(also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone
compared with an androgen receptor pathway inhibitor (ARPI, abiraterone or enzalutamide)
in participants with metastatic Hor1 expand
This Phase II study aims to evaluate efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg once a day (QD) doses + abiraterone compared with an androgen receptor pathway inhibitor (ARPI, abiraterone or enzalutamide) in participants with metastatic Hormone Sensitive Prostate Cancer (mHSPC) and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and PK data from participants randomized in the study will be evaluated Type: Interventional Start Date: Jul 2025 |
|
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, L1
Bristol-Myers Squibb
Breast Neoplasms
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific
antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload
versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin
plus gemcitabine, and capecitabine) fo1 expand
The purpose of this study is to assess the efficacy and safety of iza-bren, a bi-specific antibody-drug conjugate against EGFR and HER3 with a topoisomerase inhibitor payload versus treatment of physician's choice (TPC) (paclitaxel, nab-paclitaxel, carboplatin plus gemcitabine, and capecitabine) for the treatment of first-line metastatic triple-negative breast cancer (TNBC) or estrogen receptor (ER)-low, human epidermal growth factor receptor 2 (HER2)-negative BC patients who are not candidates for anti-PD(L)1 therapy and endocrine therapies. Type: Interventional Start Date: Sep 2025 |
|
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and1
Hoffmann-La Roche
Non-Small Cell Lung Cancer
KRAS G12C Lung Cancer
The purpose of this study is to evaluate the efficacy and safety of divarasib and
pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin,
for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or
metastatic non squamous non-small cell lung1 expand
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung cancer (NSCLC). Type: Interventional Start Date: Oct 2025 |
|
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advan1
Abbott Medical Devices
Heart Failure
Heart Diseases
Cardiovascular Diseases
Pulmonary Hypertension
The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the
HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of
ambulatory advanced heart failure patients who are not dependent on intravenous inotrope. expand
The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope. Type: Interventional Start Date: Dec 2024 |
|
A Study to Test the Effects and Safety of Riliprubart in People With Chronic Inflammatory Demyelina1
Sanofi
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Polyneuropathy, Inflammatory Demyelinating, Chronic
The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in
adult participants with CIDP whose disease is refractory to standard of care. The study
duration will be for a maximum of 111 weeks including screening, treatment phases, and
follow-up. expand
The purpose of the study is to evaluate efficacy of riliprubart compared to placebo in adult participants with CIDP whose disease is refractory to standard of care. The study duration will be for a maximum of 111 weeks including screening, treatment phases, and follow-up. Type: Interventional Start Date: Jul 2024 |
|
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Iambic Therapeutics, Inc
HER2 Mutation-Related Tumors
HER2
HER2-positive Breast Cancer
HER2 + Breast Cancer
Brain Metastases From Solid Tumors
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study
designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with
advanced cancers that harbor HER2 alterations. expand
This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study designed to evaluate the safety and preliminary efficacy of IAM1363 in participants with advanced cancers that harbor HER2 alterations. Type: Interventional Start Date: Mar 2024 |
|
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis1
Boehringer Ingelheim
Idiopathic Pulmonary Fibrosis
Progressive Pulmonary Fibrosis
This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive
pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a
previous study with a medicine called nerandomilast or BI 1015550.
The goal of this study is to find out how well people with1 expand
This study is open to people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF). They can only take part if they have completed treatment in a previous study with a medicine called nerandomilast or BI 1015550. The goal of this study is to find out how well people with pulmonary fibrosis tolerate long- term treatment with nerandomilast. The study also tests whether nerandomilast improves lung function and prolongs the time until symptoms get worse, participants need to go to the hospital, or die. Every participant takes nerandomilast as tablets for up to 1 year and 10 months. The participants may also continue their regular treatment for pulmonary fibrosis during the study. Participants visit their doctors regularly. During these visits, the doctors collect information on any health problems of the participants. Participants also regularly do lung function tests. Type: Interventional Start Date: May 2024 |
|
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Revolution Medicines, Inc.
Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Pancreatic Ductal Adenocarcinoma (PDAC)
Advanced Solid Tumors
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in
combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors. expand
This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors. Type: Interventional Start Date: Sep 2023 |
|
Strategy for Improving Stroke Treatment Response
Translational Sciences, Inc.
Ischemic Stroke
SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding
trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal
antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke. expand
SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke. Type: Interventional Start Date: Mar 2024 |
|
Aptis PRUJ Prosthesis for the Treatment of Patients With Proximal Radial Ulna Joint Disorders.
Aptis Medical
Arthritis
Unstable Radial Head
Proximal Radioulnar Joint Instability
Decreased Motion at the Proximal Radioulnar Joint and/or the Radio-humeral Joint
A Prospective, Multi-Center, Single-Arm Clinical Trial of the safety and effectiveness of
the Aptis PRUJ prosthesis for the treatment of patients with proximal radial ulna joint
disorders expand
A Prospective, Multi-Center, Single-Arm Clinical Trial of the safety and effectiveness of the Aptis PRUJ prosthesis for the treatment of patients with proximal radial ulna joint disorders Type: Interventional Start Date: Apr 2024 |
|
HEALEY ALS Platform Trial - Master Protocol
Merit E. Cudkowicz, MD
Amyotrophic Lateral Sclerosis
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial
evaluating the safety and efficacy of investigational products for the treatment of ALS. expand
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Type: Interventional Start Date: Jun 2020 |
|
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Ac1
Alliance for Clinical Trials in Oncology
B Acute Lymphoblastic Leukemia
This partially randomized phase III trial studies the side effects of inotuzumab
ozogamicin and how well it works when given with frontline chemotherapy in treating
patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal antibodies, such
as inotuzumab ozogamicin, may block cancer g1 expand
This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal antibodies, such as inotuzumab ozogamicin, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin with chemotherapy may work better in treating young adults with B acute lymphoblastic leukemia. Type: Interventional Start Date: Sep 2017 |
|
A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors
Relay Therapeutics, Inc.
Advanced NRAS-Mutant Melanoma
Advanced NRAS-Mutant Solid Tumors
NRAS Mutation
NRAS G12D
NRAS G13R
This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the
safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor
activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced
NRAS-mutant melanoma and other solid tumo1 expand
This is a Phase 1 first-in-human, open-label multicenter study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of RLY-8161, an NRAS-selective inhibitor, in participants with advanced NRAS-mutant melanoma and other solid tumors. Type: Interventional Start Date: Mar 2026 |
|
Dapagliflozin in Active Lupus Nephritis
Brigham and Women's Hospital
Lupus Nephritis (LN)
Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that
predominately impacts young people and can lead to kidney failure. Sodium-glucose
co-transporter-2 inhibitors, including dapagliflozin, are known to improve outcomes for
people with other causes of chronic kid1 expand
Lupus nephritis is a chronic and life-threatening autoimmune cause of kidney disease that predominately impacts young people and can lead to kidney failure. Sodium-glucose co-transporter-2 inhibitors, including dapagliflozin, are known to improve outcomes for people with other causes of chronic kidney disease. This pilot and feasibility randomized clinical trial will test the use of dapagliflozin versus placebo in addition to standard of care treatment for patients with early and active lupus nephritis, a group who has not been included in past trials. Type: Interventional Start Date: May 2026 |
|
BILe Acid-gut Microbiome Axis MODification Through Diet Education for Colorectal Cancer Prevention
Massachusetts General Hospital
Colorectal Cancer Prevention
Colorectal Adenoma
This research study is a prospective, single-arm clinical trial to assess the effect of a
dietary intervention for more plant-based and less animal-based food intake on secondary
bile acid production, gut microbiota, circulating biomarkers and gene expression
associated with colonic bile acid recep1 expand
This research study is a prospective, single-arm clinical trial to assess the effect of a dietary intervention for more plant-based and less animal-based food intake on secondary bile acid production, gut microbiota, circulating biomarkers and gene expression associated with colonic bile acid receptor activation and colorectal cancer. Type: Interventional Start Date: Mar 2026 |
|
Botensilimab, Balstilimab, and SBRT in Colorectal Cancer
Massachusetts General Hospital
Non-MSI-H or pMMR Colorectal Cancer With Liver Metastasis
This is a single-arm pilot feasibility study evaluating the combination of Botensilimab
and Balstilimab with Radiation Therapy (RT) in Non-Microsatellite Instability High
(MSI-H) or Proficient Mismatch Repair (pMMR) chemorefractory colorectal cancer (CRC) with
liver metastasis. expand
This is a single-arm pilot feasibility study evaluating the combination of Botensilimab and Balstilimab with Radiation Therapy (RT) in Non-Microsatellite Instability High (MSI-H) or Proficient Mismatch Repair (pMMR) chemorefractory colorectal cancer (CRC) with liver metastasis. Type: Interventional Start Date: May 2026 |
|
Finding Links Between Hot flASHes and CardioVascular Disease
Massachusetts General Hospital
Menopause-related Hot Flashes
The goal of this clinical trial is to learn if neurokinin-1/neurokinin-3 receptor
antagonist elinzanetant improves blood vessel health in women with moderate to severe hot
flashes. The main questions it aims to answer is does neurokinin-1/neurokinin-3 receptor
antagonist elinzanetant improve blood1 expand
The goal of this clinical trial is to learn if neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improves blood vessel health in women with moderate to severe hot flashes. The main questions it aims to answer is does neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improve blood vessel health? Type: Interventional Start Date: Mar 2026 |
|
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Novartis Pharmaceuticals
Small Cell Lung Carcinoma
Large Cell Neuroendocrine Carcinoma of the Lung
Neuroendocrine Prostate Cancer
Gastroenteropancreatic Neuroendocrine Carcinoma
The purpose of this study is to evaluate the safety, tolerability, dosimetry and
preliminary efficacy of [225Ac]Ac-ETN029 and the safety and imaging properties of
[111In]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3
positive cancers. expand
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [225Ac]Ac-ETN029 and the safety and imaging properties of [111In]In-ETN029 in patients aged ≥ 18 years with locally advanced or metastatic DLL3 positive cancers. Type: Interventional Start Date: Oct 2025 |
|
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Pla1
Kardigan, Inc.
Moderate Aortic Valve Stenosis
The purpose of this study is to evaluate if ataciguat slows the progression of moderate
calcific aortic valve stenosis in adults. expand
The purpose of this study is to evaluate if ataciguat slows the progression of moderate calcific aortic valve stenosis in adults. Type: Interventional Start Date: Jun 2025 |
|
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Pati1
Tango Therapeutics, Inc.
PDAC
PDAC - Pancreatic Ductal Adenocarcinoma
NSCLC
RAS Mutation
MTAP Deletion
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the
safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in
combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study
comprises a dose escalation phase and1 expand
TNG462-C102 is a Phase 1/2, open-label, multicenter study designed to determine the safety, tolerability, PK, PD, and preliminary antineoplastic activity of oral TNG462 in combination with RMC-6236, RMC-9805, mFOLFIRINOX or gemcitabine/nab-paclitaxel. The study comprises a dose escalation phase and a dose expansion phase. Type: Interventional Start Date: May 2025 |
|
Preliminary Efficacy Trial of a Digital Intervention for Depression and Cannabis Use
Massachusetts General Hospital
Depression - Major Depressive Disorder
Cannabis Use Disorder
Mental Disorder
The purpose of this study is to examine the feasibility, acceptability, and preliminary
efficacy of a digital intervention for co-occurring cannabis use and depression.
Participants will be randomized to complete Amplification of Positivity - Cannabis Use
(AMP-C) or symptom tracking. The main outco1 expand
The purpose of this study is to examine the feasibility, acceptability, and preliminary efficacy of a digital intervention for co-occurring cannabis use and depression. Participants will be randomized to complete Amplification of Positivity - Cannabis Use (AMP-C) or symptom tracking. The main outcomes will include changes in depressive symptoms and cannabis use, as well as usability ratings. Type: Interventional Start Date: Feb 2026 |
|
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovari1
Regeneron Pharmaceuticals
Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer
This study is researching an experimental drug called ubamatamab, also referred to as
"study drug". The study is focused on patients who have advanced ovarian cancer.
The aim of the study is to see how safe, tolerable, and effective the study drug is on
its own and in combination with other anti-c1 expand
This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on patients who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs (bevacizumab, cemiplimab, fianlimab and a standard chemotherapy drug, pegylated liposomal doxorubicin [PLD]), referred to as "combination drugs'. The study is looking at several other research questions, including: - What side effects may happen from taking the study drug and its experimental combinations - How much study drug and fianlimab is in the blood at different times - Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects) and its combinations Type: Interventional Start Date: May 2025 |
|
Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild1
National Institute of Allergy and Infectious Diseases (NIAID)
Major Depressive Disorder
Mild Neurocognitive Disorder
HIV
A phase II, randomized, open-label, two-arm clinical trial evaluating the safety and
efficacy of pramipexole extended release (ER) versus escitalopram for the treatment of
major depressive disorder (MDD) and comorbid MDD with mild neurocognitive disorder (MND)
in persons with HIV (PWH). Participant1 expand
A phase II, randomized, open-label, two-arm clinical trial evaluating the safety and efficacy of pramipexole extended release (ER) versus escitalopram for the treatment of major depressive disorder (MDD) and comorbid MDD with mild neurocognitive disorder (MND) in persons with HIV (PWH). Participants will be assessed comprehensively and briefly at intercurrent visits to monitor for toxicity, response to therapy, and to assess for dose changes. An optional sub-study to evaluate treatment impact on the cerebrospinal fluid (CSF) profile will be conducted in a subset of 36 participants. Type: Interventional Start Date: May 2026 |